CVAC: follow the fall
Yesterday, after releasing the unsuccessful results of CureVac vaccine, the CVAC dropped badly in the aftermarket.
This company is serious, so it won't drop its shares to zero, but many investors Betted on their new vaccine.
The fall is too steep, entrying now, on the support at 43.00 $×would be too risky. Let's following it's fall